FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 11/2023”. The Monitor is a month-to-month printed overview of enterprise capital tendencies within the European Life Sciences sector.
As of the tip of November 2023 we establish the next present VC tendencies in Europe:
- In 2023, total Life Sciences funding has reached EUR 8,390m
- Biotech acquired 41% of the entire funding quantity (-1% in comparison with the earlier month)
- Oncology dominates as the highest indication in Biotech
- VectorY Therapeutics (Netherlands) has the very best transaction quantity of EUR 129m in November, adopted by EyeBio (United Kingdom) EUR 122m and NMD Pharma (Denmark) EUR 75m
- The EIC Fund (car of the European Innovation Council, Belgium) dominates the High 5 Traders (by deal quantity), adopted by Forbion (Netherlands) and Jeito (France)
- High 5 Offers exceed EUR 130m every, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)
To entry the total report, please click on right here.
By Mathias Klozenbücher, Johannes Hyperlink and Marco Buonafede-Bennardo.